Our promise to you:
Guaranteed product quality, expert customer support.
Interleukin 8 (IL-8), or chemokine (C-X-C motif) ligand 8 (CXCL8 gene, encoding the interleukin-8 protein), also known as neutrophil chemotactic factor, is initially produced as a precursor peptide of 99 amino acids which then undergoes cleavage to create several active IL-8 isoforms. IL-8 is produced by macrophages, which secrete a 72 amino acid peptide, the major form of those active IL-8 isoforms, and other cell types, such as airway smooth muscle cells, epithelial cells and endothelial cells. CXCR1and CXCR2 are the most frequently studied GPCRs types on the surface membrane capable of binding IL-8, with different binding affinity and expressing level, and promotes the recruitment of immunosuppressive MDSCs (myeloid-derived suppressor cells). IL-8 plays a key role in inducing the cell signaling necessary to bring about these changes, such as recruitment of neutrophils to the site of damage or infection, stimulating phagocytosis and promoting angiogenesis.
Role of IL-8 in cancer
It has been found that tumors very frequently coopt the production of this chemokine, which exerts different pro-tumoral functions. Both tumor and tumor-associated stromal cells can upregulate production of IL-8, causing MDSCs to migrate to the tumor microenvironment where they suppress the antitumor immune response, locally provide growth factors and expand the stroma. Reportedly, these include angiogenesis, which has been mentioned above, and survival signaling for cancer stem cells. Given the fact that in cancer patients IL-8 is mainly produced by tumor cells themselves, its serum concentration has been shown to correlate with tumor burden. Thus, IL-8 serum concentrations have been shown to be useful pharmacodynamic biomarker to early detect response to immunotherapy. Since the roles that IL-8 plays in favoring tumor progression, inhibition of IL-8 may reduce these tumorigenic effects. Several therapeutic strategies have been developing to interfere with its functions. Such interventions hold promise, especially for therapeutic combinations in the field of cancer immunotherapy.
Fig 1. Interleukin-8 in cancer pathogenesis, treatment and follow-up (Carlos Alfaro, etc. 2017)
IL-8 Gene Editing Service
CRISPR/Cas9 PlatformCB, a global leading biotechnological company specializing in gene editing, is dedicated to offering comprehensive CRISPR/Cas9 gene editing services and products for academic research, biotech research and pharmaceutical drug discovery. With deep gene editing knowledge and extensive experience in experimental operation and data processing, we help you effectively control target genes knockout/knockin/point mutation in cells or animals via CRISPR/Cas9 technology.
Our professional scientists have successfully implemented IL-8 CRISPR/Cas9 gene edited in both easy-to-transfect cell lines and hard-to-transfect cells. To support your research projects, we will offer you comprehensive custom IL-8 gene editing service from strategy design to final stable cells. Our IL-8 gene editing cell line generation services include:
➢ gRNA design and synthesis
➢ Transfect the cell lines you're interested
➢ Select the high expression cells and sort monoclonal cell
➢ Validate the knock-out/knock-in/point mutation of IL-8 by PCR and sequencing
➢ Produce cryogenic preserved vials of stable cells and a final report
Typically, we develop and validate CRISPR-mediated gene editing cell lines including HEK239T, Hela, HepG2, U87, and other cell lines according to your requirements.
Other host cell lines available: Ba/F3, CHO, RAW, RAW264.7, etc. Additionally, we can also supply you our transfected reporter stable cell lines, such as IL-8-Luc Reporter Cell Line and Mouse IL-8 LUCPorter stable cell lines.
CRISPR/Cas9 PlatformCB also has extensive experience in incorporating CRISPR-Cas9 technology into animal models, which have been fully recognized by our clients. Tell us your projects' needs, we provide a one-stop-shop IL-8 CRISPR/Cas9 gene editing animal service with shorter turnaround time and lower price. Our IL-8 gene editing animal model generation services include:
➢ IL-8 gene conventional knock-out animals
➢ IL-8 gene conditional knock-out animals
➢ IL-8 point mutation animals
➢ IL-8 knock-in animals
Alternative species: mouse, rat, rabbit, zebrafish, C. elegans, etc.
CRISPR/Cas9 PlatformCB is dedicated to providing the best gene editing services to accelerate the achievement of your research goals. With skilled and experienced genomics experts, we are able to provide our clients with professional and efficient custom CRISPR/Cas9 services to meet your special requirements. We are committed to providing the most reliable and effective research services and products to best meet your research goals with excellent quality management and quality assurance capacity. If you have any questions, please feel free to contact us.
Related Products at CRISPR/Cas9 PlatformCB